Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
- License Information
-
More Information
Article History
Received: 16 October 2025
Revised: 23 January 2026
Accepted: 26 January 2026
First Online: 7 February 2026
Declarations
:
: The manuscript does not contain clinical studies or patient data.
: C. Bakewell receives consulting and/or speaker honoraria from AbbVie, Johnson & Johnson, Bristol Myers Squibb, Eli Lilly, Pfizer, UCB, Sanofi, and Novartis. A. Deodhar has advisory board memberships with Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, and UCB, speaker engagements for Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB, and research grants from Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, MoonLake, Novartis, Pfizer, and UCB. G.C. Wright has served as a consultant for AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Fate Therapeutics, Johnson & Johnson, Eli Lilly, Novartis, Pfizer, Sanofi, Scipher Medicine, and UCB.
